Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Magnesium is neuroprotective in neonatal animal models of acquired hypoxic-ischemic and/or inflammatory cerebral lesions. It is associated with a significant reduction of perinatal death and cerebral palsy in some observational studies.

The objective of the study is to assess if prenatal magnesium sulfate given to women at risk of preterm birth before 33 week's gestation is neuroprotective.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Rouen
• Collaborator: Ministry of Health, France
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• women pregnant with single, twin or triplet very preterm fetuses younger than 33 week's gestational age if birth was expected or planned within 24 hours

Exclusion Criteria:

• women with vascular disease of pregnancy

• women with severe malformation or chromosomal abnormalities in the fetus

• women with hypotension

• renal insufficiency

• cardiac rhythmic abnormalities

• intake of calcium channel inhibitors

• digitalis or indomethacin less than 24 hours

• persistence of signs of cardiovascular toxicity or tachycardia for more than one hour after cessation of betamimetic intake

• myasthenia

• emergency C section